Bafetinib

• CAT Number: I005159
• CAS Number: 859212-16-1
• Molecular Formula: C₃₀H₃₁F₃N₈O
• Molecular Weight: 576.62
• Purity: ≥95%
• Target: Bcr-Abl/Lyn
• Solubility: DMSO: ≥ 42 mg/mL
• Storage: 3 years -20℃ powder
• IC50: 5.8 nM/19 nM [2]
• IUPAC Name: 4-[[(3S)-3-(dimethylamino)pyrrolidin-1-yl]methyl]-N-[4-methyl-3-[(4-pyrimidin-5-ylpyrimidin-2-yl)amino]phenyl]-3-(trifluoromethyl)benzamide
• InChI: InChI=1S/C30H31F3N8O/c1-19-4-7-23(13-27(19)39-29-36-10-8-26(38-29)22-14-34-18-35-15-22)37-28(42)20-5-6-21(25(12-
• InChIKey: ZGBAJMQHJDFTQJ-DEOSSOPVSA-N
• SMILES: CC1=C(C=C(C=C1)NC(=O)C2=CC(=C(C=C2)CN3CCC(C3)N(C)C)C(F)(F)F)NC4=NC=CC(=N4)C5=CN=CN=C5

Bafetinib (Cat.No:I005159) is a potent and selective dual Abl/Lyn kinase inhibitor. It has been investigated for the treatment of various types of cancers, including leukemia, breast cancer, and lung cancer. Bafetinib has also shown promising results in the treatment of Alzheimer’s disease and multiple sclerosis. However, further clinical trials are required to evaluate its efficacy and safety in these indications.

Reference

[1]. Grace MS, et al. The tyrosine kinase inhibitor bafetinib inhibits PAR2-induced activation of TRPV4 channels in vitro and pain in vivo. Br J Pharmacol. 2014 Aug;171(16):3881-3894.
[2]. Kimura S, et al. NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood. 2005 Dec 1;106(12):3948-3954.